Cofttek holdings limited

Wnt&Beta catenin

TD139 (1450824-22-2)

TD-139 is a galectin-3 inhibitor potentially for the treatment of idiopathic pulmonary fibrosis (IPF)

Not Intended for Therapeutic Use. For research use only.

CAS: 1450824-22-2 Category

TD139 (1450824-22-2) Description

TD-139 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to [email protected] to inquire quote.


TD139 (1450824-22-2) Specifications

Product Name TD139
Synonym  TD-139; TD139; TD 139
Chemical Name (2R,2’R,3R,3’R,4S,4’S,5R,5’R,6S,6’S)-6,6′-thiobis(4-(4-(3-fluorophenyl)-1H-1,2,3-triazol-1-yl)-2-(hydroxymethyl)tetrahydro-2H-pyran-3,5-diol)
Drug Class N/A
Purity ≥ >98%
CAS Number  1450824-22-2
Molecular Formula C₂₈H₃₀F₂N₆O₈S
Molecular Weight 648.64
Monoisotopic Mass 393.15494
MDL number SML0795
InChi Code   InChI=1S/C28H30F2N6O8S/c29-15-5-1-3-13(7-15)17-9-35(33-31-17)21-23(39)19(11-37)43-27(25(21)41)45-28-26(42)22(24(40)20(12-38)44-28)36-10-18(32-34-36)14-4-2-6-16(30)8-14/h1-10,19-28,37-42H,11-12H2/t19-,20-,21+,22+,23+,24+,25-,26-,27+,28+/m1/s1
SMILES O[[email protected]]([[email protected]@H](N1N=NC(C2=CC=CC(F)=C2)=C1)[[email protected]]([[email protected]@H](CO)O3)O)[[email protected]@H]3S[[email protected]]4[[email protected]@H]([[email protected]@H](N5N=NC(C6=CC=CC(F)=C6)=C5)[[email protected]]([[email protected]@H](CO)O4)O)O
Form N/A
Color Crystalline
Solubility  Soluble in DMSO
Storage Temp.  0 – 4 C for short term (days to weeks), or -20 C for long term (months)
Shelf life > >2 years if stored properly
Handling Protect from air and light
Application For Research Use Only! Not For Use in Humans.



RIDADR NONH for all modes of transport


[1]. Madan B, McDonald MJ, Foxa GE, Diegel CR, Williams BO, Virshup DM. Bone Res. 2018 May 25;6:17. doi: 10.1038/s41413-018-0017-8. eCollection 2018.

[2]. .Katoh M. Int J Oncol. 2017 Nov;51(5):1357-1369. doi: 10.3892/ijo.2017.4129. Epub 2017 Sep 19. Review.

[3]. Katoh M, Katoh M. Int J Mol Med. 2017 Sep;40(3):587-606. doi: 10.3892/ijmm.2017.3071. Epub 2017 Jul 19.

[4].Madan B, Ke Z, Lei ZD, Oliver FA, Oshima M, Lee MA, Rozen S, Virshup DM. Oncotarget. 2016 Mar 15;7(11):12386-92. doi: 10.18632/oncotarget.7157.

[5]. Madan B, Ke Z, Harmston N, Ho SY, Frois AO, Alam J, Jeyaraj DA, Pendharkar V, Ghosh K, Virshup IH, Manoharan V, Ong EH, Sangthongpitag K, Hill J, Petretto E, Keller TH, Lee MA, Matter A, Virshup DM. Oncogene. 2016 Apr 28;35(17):2197-207. doi: 10.1038/onc.2015.280. Epub 2015 Aug 10.